Kidney cancer patients may soon have more treatment choices that provide a higher quality of life, thanks to research completed by physician scientists at the University of Texas (UT) Southwestern Medical Center. Their recent study showed that treating metastatic kidney cancer with an advanced and focused form of radiation called stereotactic ablative radiation therapy achieves more than 90 percent control of local tumors, and offers the possibility of safely delaying systemic therapy. “This study shows that stereotactic radiation provides a good noninvasive alternative to conventional treatment such as surgery, and that it effectively controls the disease,” said Raquibul Hannan (photo), MD, PhD, Assistant Professor of Radiation Oncology and Co-Leader of the Kidney Cancer Program of the Harold C. Simmons Comprehensive Cancer Center and senior author of the study. “It may also offer an alternative to patients who are not candidates for surgery. Often due to the number and location of the metastases and sometimes due to other conditions, patients are not candidates for surgery.” The standard of care for metastatic renal cell carcinoma is systemic therapy, which can be associated with significant side effects like tiredness, fatigue, high blood pressure, and rash.
Login Or Register To Read Full Story